Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + lenalidomide + rituximab (OLR) in newly treated mantle cell lymphoma
ChiCTR2200061041Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in mantle cell lymphoma (MCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Complete response rate (CRR). Planned start Jun 2022; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR2200061041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061041.